Changes in serum lipids, plasma fibrinogen and other haemostatic parameters induced by ciprofibrat action in hyperlipidemic patients with and without coronary artery disease;Modificaciones de los lípidos séricos, el fibrinógeno y otros parámetros hemostáticos por acción del ciprofibrato, en pacientes hiperlipidémicos con y sin enfermedad arterial coronaria

Investigacion Clinica

Volumn 47, Issue 1, 2006, Pages

  Espinosa, Raúl A ^a,e   Rodríguez Roa, Elsy ^b   Nagy, Elena ^c   Mijares, Mercedes E ^c   Rodríguez Larralde, Álvaro ^d   Gil, Amparo ^d   Lundberg, Ulf ^d   Carvajal, Zoila ^d   Castillo, Luis ^a   Arocha Piñango, Carmen L ^d  

^a Hospital Miguel Perez Carreno   (Venezuela)

^b Hospital José Ignacio Baldó   (Venezuela)

^c Servicio de Banco de Sangre del HMPC   (United States)

^d INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^e Prados del Este   (Venezuela)

Author keywords

Atherothrombosis; Ciprofibrat; Fibrinogen; Haemostatic parameters; Serum lipids

Indexed keywords

BLOOD CLOTTING FACTOR 7; CHOLESTEROL; CIPROFIBRATE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PROTEIN C; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VON WILLEBRAND FACTOR; ANTILIPEMIC AGENT; CLOFIBRIC ACID; DRUG DERIVATIVE; LIPOPROTEIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANGIOCARDIOGRAPHY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG MECHANISM; ELECTROCARDIOGRAM; EXERCISE TEST; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; HEMOSTASIS; HUMAN; HYPERLIPIDEMIA; LABORATORY TEST; LIPID ANALYSIS; LIPID BLOOD LEVEL; MALE; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; ADOLESCENT; ADULT; AGED; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; MIDDLE AGED; PILOT STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ANTILIPEMIC AGENTS; CHOLESTEROL; CLOFIBRIC ACID; CORONARY ARTERIOSCLEROSIS; FEMALE; FIBRINOGEN; HEMOSTASIS; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 84858876691     PISSN: 05355133     EISSN: 05355133     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Hoeg JM. Evaluating coronary heart disease risk: tiles in the mosaic. J Am Med Assoc 1997; 277:1387-1390.
2. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson ID, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2:533-537.
3. Thompson SG, Kienast J, Pyke SMD, Haverkate, F, van de Loo JCW for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris study group. Hemostatic factors and the risk of myocardial infarction on sudden death in patients with angina pectoris. N Engl J Med 1995; 332:635-641.
4. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, c-reactive protein, albumin or leukocyte count with coronary heart disease. Meta-analyses of prospective studies. J Am Med Assoc 1998; 279:1477-1482.
5. Maresca G, Di Blasio A, Marchioli R, Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction. An update. Arterioscler Thromb Vasc Biol 1999; 19:1368-1377.
6. Folsom AR, Rosamond WD, Shahar E, Cooper LS, Aleksic N, Nieto FJ, Rasmussen ML, Wu KK for the Atherosclerosis Risk in Communities (ARIC) Study Investigators. Prospective study of markers of hemostatic function with risk in ischemic stroke. Circulation 1999; 100:736-742.
7. Lauribe P, Benchimol D, Dartigues JF, Dada S, Benchimol H, Drouillet F, Bonnet J, Bricaud H. Biological risk factors for sudden death in patients with coronary artery disease and without heart failure. Int J Cardiol 1992; 34:307-318.
8. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94:2057-2063.
9. Cortellano M, Boschetti C, Cofrancesco E, Zanussi C, Catalano M, de Gaetano G and The PLAT Study Group. The PLAT Study: a multidisciplinary study of hemostatic function and conventional risk factors in vascular disease patients. Atherosclerosis 1991; 90: 109-118.
10. ECAT Angina Pectoris Study Group. ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14:8-17.
11. Drouet L. Atherothrombosis as a systemic disease. Cerebrovasc Dis 2002; 13 (suppl 1):1-6.
12. World Health Organization. The world health report 2001. Geneva: WHO, 2001.
13. La Rosa JC, He J, Vupputuri S. Effect of statin on risk of coronary disease. A metaanalysis of randomised controlled trials. J Am Med Assoc 1999; 282:2340-2346.
14. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. J Am Med Assoc 1998; 279:1643-1650.
15. Sprecher DL, Watkins TR, Behar S, Brown WV, Rubins HB, Schaefer EJ. Importance of high-density lipoprotein cholesterol and triglyceride levels in coronary heart disease. Am J Cardiol 2003; 91: 575-580.
16. Schonfeld G. The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis 1994; 111: 161-174.
17. Maison P, Mennen L, Sapinho D, Balkau B, Sigalas J, Chesnier MC, Eschwège E for DESIR Study Group. A pharmacoepidemiological assessment of the effect of statin and fibrates on fibrinogen concentration. Atherosclerosis 2002; 160: 155-160.
18. Arocha-Piñango CL, Rodríguez-Larralde A, Apitz R, Lundberg U, Carvajal Z, Ojeda A, López F, Gil A, Nagy E, Mijares ME, Esparragoza I, Cova A, Espinosa R, Velásquez L, González X, Rodríguez I, Uzcategui R, González N, Hernández H, Mistichio F, Calderas C, Febles J, Gamboa L, Rodríguez F, Vera M, de Yilales MA, Morales MJ, Avila C, Marling I, de Pesante L, Hernández A, Pérez-Requejo JL, Lucena O, Carreño A, Coll E, Moreno B, Novel A, Soto L, Sánchez HS, Diez-Ewald MP, Ryder E, Vizcaíno G, Vizcaíno M, Torres E, Sulbarán T, de Roa E, Castro P, Valecillos E, Fuenmayor M, Camejo L, Rivero F. El fibrinógeno: su relación con la enfermedad arterial coronaria. Resultados preliminares de un estudio multicéntrico. Rev Chilena Cardiol 1996; 15: 66-77.
19. Espinosa RA, por el Grupo FRICVE. El fibrinógeno: factor de riesgo cardiovascular. Invest Clin 2002; 43:291-301.
20. Betteridge DJ. Ciprofibrate - a profile. Postgrag Med J 1993; 69 (suppl 1): S42-S49.
21. Krauss RM, Deckelbaum RJ, Ernst N, Fisher E, Howard BV, Knopp RH, Kotchen T, Lichtenstein AH, Mc Gill HC, Pearson TA, Prewitt E, Stone NJ, Van Horn L, Weinberg R. Dietary guidelines for healthy American adults: a statement for health professionals from the Nutrition Committee American Heart Association. Circulation 1996; 94:1795-1800.
22. Bosch V, Rodriguez M, Geron N. Características de las lipoproteínas más frecuentes en Venezuela, estudiadas mediante un análisis de centrifugación preparativa. Invest Clin 1987; 28:5-19.
23. Ingram GIC. The determination of plasma fibrinogen by the clot weight method. Biochem J 1952; 51:583-585.
24. Thomson JM. Blood coagulation and haemostasis. A practical guide. Churchil, Ed. Livingston, London 1991.
25. Holvoet P, Cleenpuy H, Collen D. Assay of human tissue-type plasminogen activator (tPA) with an enzyme-linked immunoabsorbent assay (ELISA) based on three murine monoclonal antibodies to tPA. Thromb Haemost 1983; 54:684-687.
26. Bruce RA, De Rouen TA, Hossack HF Value of maximal exercise test and risk assessment of primary coronary heart disease events in healthy men. Am J Cardiol 1980; 46:371-378.
27. Oro L, Carlson LA, Olsson A, Poole PH. Long-term efficacy and safety of Ciprofibrate in patients with primary hyperlipidemia. Curr Ther Res 1992; 51: 750-762.
28. Wood D, De Backer G, Faergeman O, Graham I, Maucia I, Pyorala K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998; 140:199-270.
29. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adults Treatment Panel ATP III). Final report. Circulation 2002; 106: 3143-3421.
30. Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003; 171:1-13.
31. Chapman MJ, Bruckert E. The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy. Atherosclerosis 1996; 124 (suppl): S21-S28.
32. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease: the PROCAM experience. Am J Cardiol 1992; 70: 733-737.
33. Grundy SM, Vega GL. Two different views of the relationship of hypertriglyceridemia to coronary artery disease. Arch Intern Med 1992; 152: 28-34.
34. Simpson IA, Lorimer AR, Walker ID, Davidson JF. Effect of ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolaemia. Thromb Haemost 1985; 54: 442-444.
35. Branchi A, Rovellini A, Sommariva D, Gugliandolo AC, Fasoli A. Effect of three fibrate derivates and two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb Haemost 1993; 70: 241-243.
36. de Maat MPM, Knipscheer HC, Kastelein JJP, Kluft C. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia. Thromb Haemost 1997; 77:75-79.
37. de Maat MPM. Effects of diet, drugs and genes on plasma fibrinogen levels. Ann N Y Acad Sci 2001; 936:509-521.
38. Chambless LE, McMahon R, Wu K, Folsom A, Finch A, Shen YL. Short-term intraindividual variability in hemostasis factors. The Atherosclerosis Risk in Communities (ARIC) study: intraindividual variability study. Ann Epidemiol 1992; 2:723-733.
39. Rosenson RS, Mosca L, Staffileno BA, Tangney CC. Variability in fibrinogen measurements: an obstacle to cardiovascular risk stratification. Atherosclerosis 2001; 159:225-230.
40. Kovács I, Tarján J, Császár A. Effect of ciprofibrate on the endothelial dysfunction of patients with combined dyslipidemia. Orv Hetil 2001; 142:775-779.
41. Kontopoulos AG, Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Mayroudi MC, Boudoulas H. Effects of simvastatin and Ciprofifrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hiperlipidaemia and coronary artery disease. Cor Artery Dis 1996; 7:843-850.
42. Papadakis JA, Ganotakis ES, Jagroop IA, Winder AF, Mikhailidis DP. Statin plus Fibrate combination therapy: fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Int J Cardiol 1999; 69:237-244.
43. Krysiak R, Okopien B, Herman ZS. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 2003; 63:1821-1854.